

AMENDMENT UNDER 37 C.F.R. § 1.111
U.S. Application Number: 10/662,358
Attorney Docket Number: Q77446

REMARKS

Upon entry of the Amendment, Claims 6-12 and 14 are all the claims pending in the application. Claims 6-9, 11-12, and 14 have been amended. Support for these amendments are found in the specification, such as on page 3. Therefore, no new matter has been added.

Claims 6-14 have been rejected under 35 U.S.C. § 112, first paragraph, as allegedly failing to comply with the written description requirement.

Applicants respectfully traverse this rejection.

Claim 6 is presently drawn to an *E. coli* and recites a PHA synthase gene of *Pseudomonas* species.

Example 1 of Applicants' specification describes producing recombinant *E. coli*. Example 1 describes that a mutant *E. coli* WB101 had the *fadB* gene deleted and was transformed with the MCL-PHA synthase gene recombinant vector and the MaoC recombinant vectors. Example 1 also describes that a mutant *E. coli* WB106 had both the *fadB* and *maoC* genes deleted and was transformed with the MCL-PHA synthase gene recombinant vector and the MaoC recombinant vectors. In this regard, the specification provides written description support for the *E. coli*.

Further, Example 1 of Applicants' specification describes the construction of p10499613C2. Example 1-2 describes that a promoter the PHA synthase gene of *Pseudomonas* sp. 61-3 was inserted into pTrc99A (Pharmacia Biotech Co.) to produce p10499613C2. Example 1-5 describes that the *E. coli* was transformed with p10499613C2 to produce *E. coli* WB101 and

AMENDMENT UNDER 37 C.F.R. § 1.111
U.S. Application Number: 10/662,358
Attorney Docket Number: Q77446

E. coli WB106. In this regard, the specification provides written description support for the PHA synthase gene of *Pseudomonas* species.

Claims 6-14 have been rejected under 35 U.S.C. § 112, first paragraph, as allegedly failing to comply with the enablement requirement.

Applicants respectfully traverse this rejection.

Example 1 describes isolating and transforming *E. coli* hosts with PHA synthase gene of the *Pseudomonas* species to produce *E. coli* WB101 and *E. coli* WB106. Example 2 describes that *E. coli* WB101 and the *E. coli* WB106 transformed with the MaoC gene were cultured in LB medium and decanoate to produce MCL-PHA. In this regard, a person skilled in the art can make and use the *E. coli* recited in Claim 6 without undue experimentation.


Furthermore, Claims 7-14 depend from Claim 6. Therefore, Claims 7-14 are patentable for at least the same reasons as Claim 6.

In view of the above, reconsideration and allowance of this application are now believed to be in order, and such actions are hereby solicited. If any points remain in issue which the Examiner feels may be best resolved through a personal or telephone interview, the Examiner is kindly requested to contact the undersigned at the telephone number listed below.

AMENDMENT UNDER 37 C.F.R. § 1.111
U.S. Application Number: 10/662,358
Attorney Docket Number: Q77446

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.

Respectfully submitted,

 Reg No 58490
Sunny Lee
Registration No. 53,982

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE
23373
CUSTOMER NUMBER

Date: July 7, 2006